Drugs / Activated NK
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03634501 | Oct 2018 → Sep 2021 | breast cancer, colon carcinoma, lung cancer, malignant pancreatic neoplasm +1 | Xuanwu Hospital, Beijing | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Activated NK | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03634501 ↗ |
| Modality | Cell therapy | “NK cell therapy” NCT03634501 ↗ |
| Route | Intravenous | “Subjects will receive NK cell treatment by intravenous infusion.” NCT03634501 ↗ |